← Leaderboards
Krystof S Bankiewicz
Ohio State University
$27,032,201
Attributed
$29,002,589
Total exposure
13
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.1M · FY2006–25$10M$7.5M$5M$2.5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$29,002,589 · 13
By mechanism
R01$23,040,224 · 4
UG3$2,344,724 · 1
UH3$1,596,053 · 1
R21$743,155 · 2
U54$654,544 · 4
U19$623,889 · 1
Top collaborators
- Niren Murthy5 shared
Most similar at Ohio State University
Same institution · by research overlap
- Norton H Neff$1,314,000
- Jeffrey A. Wojton$38,467
- Victor Steven Van Laar$951,237
Others in their field
Top investigators on “Brain”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Michael W Weiner · Northern California Institute Res &Educ$149,959,854
- David A Bennett · Rush University Medical Center$148,375,056
- David Heimbrook · Leidos Biomedical Research, Inc.$145,442,397
- Walter John Curran · Thomas Jefferson University$114,442,832
- Hongkui Zeng · Allen Institute$113,960,965
Research focus
BrainCorpus Striatum StructureGene TherapyVectorProgramsMagnetic Resonance ImagingNeurologicInfusion ProceduresBaseNeuronsDopamineEnzymesGenesSafetyClinical TrialsClinicSymptomsCohortBrain RegionProceduresDoseConvectionNervous System DisorderNonhuman Primate
Grant awards (39)
A Safety and Efficacy Study of AAV2-hAADC for AADC Deficiency$2,242,039
R01 · FY2025 · NS · contact PI
Research Project I: AAV-CRISPR to Treat Huntington's Disease$623,889
U19 · FY2025 · NS · contact PI
A Safety and Efficacy Study of AAV2-hAADC for AADC Deficiency$2,665,330
R01 · FY2024 · NS · contact PI
A Safety and Efficacy Study of AAV2-hAADC for AADC Deficiency$3,470,061
R01 · FY2022 · NS · contact PI
Development of a Nanoparticle-Based Gene Editing Technology for Neurological Applications$1,096,057
UH3 · FY2022 · NS · contact PI
Development of a nanoparticle-based gene editing technology for neurological applications$499,996
UH3 · FY2022 · NS · contact PI
A Safety and Efficacy study of AAV2-hAADC for AADC deficiency$3,683,088
R01 · FY2021 · NS · contact PI
Development of a Nanoparticle-Based Gene Editing Technology for Neurological Applications$782,842
UG3 · FY2021 · NS · contact PI
Development of a nanoparticle-based gene editing technology for neurological applications$782,572
UG3 · FY2020 · NS · contact PI
Validation of a single-pass surgical trajectory to enable AAV2-hAADC infusion into brainstem and mid-brain in nonhuman primate$429,000
R21 · FY2020 · NS · contact PI
Development of a nanoparticle-based gene editing technology for neurological applications$779,310
UG3 · FY2019 · NS · contact PI
A Safety and Efficacy study of AAV2-hAADC for AADC deficiency$412,592
R01 · FY2019 · NS · contact PI
A Safety and Efficacy study of AAV2-hAADC for AADC deficiency$493,460
R01 · FY2018 · NS · contact PI
A Safety and Efficacy study of AAV2-hAADC for AADC deficiency$138,563
R01 · FY2018 · NS · contact PI
A Safety and Efficacy study of AAV2-hAADC for AADC deficiency$126,850
R01 · FY2018 · NS · contact PI
A Safety and Efficacy study of AAV2-hAADC for AADC deficiency$883,538
R01 · FY2017 · NS · contact PI
A Safety and Efficacy study of AAV2-hAADC for AADC deficiency$967,730
R01 · FY2016 · NS · contact PI
Translational AAV Delivery Platform to the Brain$459,695
R01 · FY2015 · NS · contact PI
Translational AAV Delivery Platform to the Brain$553,499
R01 · FY2014 · NS · contact PI
Translational AAV Delivery Platform to the Brain$564,073
R01 · FY2013 · NS · contact PI
Translational AAV Delivery Platform to the Brain$601,166
R01 · FY2012 · NS · contact PI
Translational AAV Delivery Platform to the Brain$579,260
R01 · FY2011 · NS · contact PI
Preclinical development of a gene therapy for Niemann-Pick disease, type A$38,316
R01 · FY2011 · NS · contact PI
Focal Dopamine Indicated in Dyskinesias in MPTP Monkeys$448,164
R01 · FY2010 · NS · contact PI
Focal Dopamine Indicated in Dyskinesias in MPTP Monkeys$278,100
R01 · FY2010 · NS · contact PI
Preclinical development of a gene therapy for Niemann-Pick disease, type A$578,650
R01 · FY2009 · NS · contact PI
Focal Dopamine Indicated in Dyskinesias in MPTP Monkeys$562,702
R01 · FY2009 · NS · contact PI
Preclinical development of a gene therapy for Niemann-Pick disease, type A$289,326
R01 · FY2009 · NS · contact PI
Focal Dopamine Indicated in Dyskinesias in MPTP Monkeys$620,252
R01 · FY2008 · NS · contact PI
Preclinical development of a gene therapy for Niemann-Pick disease, type A$561,799
R01 · FY2008 · NS · contact PI
Focal Dopamine Indicated in Dyskinesias in MPTP Monkeys$622,963
R01 · FY2007 · NS · contact PI
Preclinical development of a gene therapy for Niemann-Pick disease, type A$560,267
R01 · FY2007 · NS · contact PI
Focal Dopamine Indicated in Dyskinesias in MPTP Monkeys$638,741
R01 · FY2006 · NS · contact PI
Enzymatic Replacement in PD Monkeys by Gene Transfer$151,004
R21 · FY2003 · NS
Enzymatic gene transfer in MPTP animals$163,636
U54 · FY2002 · NS
Analysis of vector and transgene product transport$163,636
U54 · FY2002 · NS
Enhanced delivery method for distribution of lentiviral and AAV vectors$163,636
U54 · FY2002 · NS
Trophic gene transfer in MPTP animals$163,636
U54 · FY2002 · NS
Enzymatic Replacement in PD Monkeys by Gene Transfer$163,151
R21 · FY2002 · NS